Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Evotec SE

Market Cap 823M 944M 762M 714M 1.34B 89.06B 1.35B 9.04B 3.5B 43.84B 3.54B 3.47B 152B P/E 2026 *
-6.52x
P/E 2027 * -23.7x
Enterprise Value 837M 960M 775M 726M 1.36B 90.61B 1.37B 9.2B 3.57B 44.6B 3.6B 3.53B 155B EV / Sales 2026 *
1.14x
EV / Sales 2027 * 1.09x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+27.67%
3 months+27.67%
6 months-16.48%
Current year-16.48%
Current year 4.72
Extreme 4.725
6.69
1 year 4.72
Extreme 4.725
8.58
3 years 4.72
Extreme 4.725
25.48
5 years 4.72
Extreme 4.725
52.21
10 years 4.25
Extreme 4.25
52.21
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 43 2022-06-21
Change 5-day change 1-year change 3-year change Capi.($)
+27.67%-.--% - - 926M
+1.44%+1.36%-10.88%-12.14% 42.75B
+3.31%+9.22%+308.19%+562.02% 34.65B
+2.84%+3.80%+6.87%+34.93% 30.03B
-1.70%-7.34%+8.51%-22.34% 28B
-1.90%+2.47%+10.18%+18.13% 24.83B
-0.14%+7.06% - - 14.34B
+0.68%-3.13%+52.04%+107.47% 13.14B
-0.57%-2.83%+3.34%+1.66% 12.61B
-0.26%+0.41%+100.27%+80.69% 12.25B
Average +3.12%+0.55%+59.81%+96.30% 23.62B
Weighted average by Cap. +0.85%+0.91%+64.89%+112.23%

Financials

2026 *2027 *
Net sales 738M 846M 683M 640M 1.2B 79.82B 1.21B 8.1B 3.14B 39.29B 3.18B 3.11B 136B 818M 938M 757M 709M 1.33B 88.51B 1.34B 8.99B 3.48B 43.56B 3.52B 3.45B 151B
Net income -113M -130M -105M -98.17M -184M -12.25B -185M -1.24B -482M -6.03B -487M -477M -20.94B -30.42M -34.89M -28.18M -26.38M -49.47M -3.29B -49.76M -334M -130M -1.62B -131M -128M -5.63B
Net Debt 14.3M 16.4M 13.24M 12.4M 23.25M 1.55B 23.39M 157M 60.89M 762M 61.56M 60.24M 2.64B 69.32M 79.51M 64.21M 60.1M 113M 7.5B 113M 762M 295M 3.69B 298M 292M 12.82B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.630EUR
Average target price
6.443EUR
Spread / Average Target
+39.15%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!